Regeneron pays $1M milestone payment to Medigene
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2024
0mins
Milestone Payment Announcement: Medigene received a $1M milestone payment from Regeneron due to the development progress of the MAGE-A4-TCR program, which was part of Regeneron's acquisition of 2seventy Bio's oncology and autoimmune cell therapy pipeline.
Trial Development in China: The payment was triggered by a trial milestone in China, where JW Therapeutics is leading the development of Regeneron's MAGE-A4 cell therapy that utilizes a T cell receptor generated by Medigene.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





